Several new drugs have recently entered the PsA market, including new entries into the biologic disease-modifying antirheumatic drug (bDMARD) and targeted synthetic disease-modifying antirheumatic drug (tsDMARD) classes. However, the impact of these newer therapies on the treatment algorithm is not yet understood; the data in this report provide insight into this question. Physicians are choosing among six tumor necrosis factor (TNF) inhibitors, including a biosimilar version of Remicade, but they may also select from two interleukin-17 (IL-17) inhibitors, an IL-12/23i, a phosphodiesterase-4 inhibitor (PDE4) inhibitor, a Janus kinase (JAK) inhibitor, and a selective costimulation modulator. With this plethora of drugs, understanding what choices physicians make and why they prefer or avoid certain drugs is increasingly important for manufacturers.


  • How do dermatologists and rheumatologists differ in their approach to treating PsA? How many patients have received a previous diagnosis of a related disease?
  • Where in the treatment algorithm will new therapies such as Taltz, Xeljanz, and Orencia fall?
  • What factors drive physicians to switch patients away from the heavilyused TNF inhibitors? How many TNF inhibitors will be tried for a given patient before physicians move to an alternative class of therapy?
  • Under what circumstances will physicians select a biosimilar TNF inhibitor instead of a branded version? How important is cost when making prescribing decisions?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.

Markets covered:United States.

Primary research: Survey of 50 rheumatologists and 50 dermatologists.

Key drugs covered: Remicade, Humira, Stelara, Cosentyx, Xeljanz, Orencia, Otezla.

Key insights provided:

  • Factors influencing disease management and treatment decisions.
  • Drivers of and constraints ontreatment selection.
  • Physician-reported treatment practices and brand-level patient shares.
  • Rationale for changes in treatment approach.
  • Physician insight intopersistency and compliance.
  • Physician-reported recent/anticipated changes in brand usage or treatment approach.

Table of contents

  • Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis (US)

Author(s): Kristine Mackin, PhD

Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.

She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.

Related Reports

Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast

PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdia...

View Details

Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

View Details

Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2019

PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnose...

View Details